2 diabetes drugs up for FDA safety review in April

03/9/2009 | CNNMoney

An FDA advisory committee is scheduled next month to examine whether Bristol-Myers Squibb's saxagliptin and Novo Nordisk's liraglutide increase the risks of heart attack and stroke in patients with Type 2 diabetes. The move is in line with the agency's guidance issued in December.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA